Neoplasm

MOLLI Surgical Unveils OncoPen, a New Surgical Tool for Empowering Precision and Confidence in the Operating Room

Retrieved on: 
Tuesday, April 9, 2024
Prevalence, Patient, Cancer, Surgeon, Neoplasm, Breast cancer, Surgical oncology, Health, Birth control

DEERFIELD, Ill., April 9, 2024 /PRNewswire/ -- MOLLI Surgical continues to push the boundaries of surgical care with the launch of OncoPen™, a minimally invasive surgical tool designed to empower surgeons and improve outcomes for patients affected with breast cancer. The sleek, pen-like wand seamlessly integrates with the award-winning MOLLI® 2 System, offering sophisticated tools for precisely targeting and removing cancerous lesions.

Key Points: 
  • The sleek, pen-like wand seamlessly integrates with the award-winning MOLLI® 2 System , offering sophisticated tools for precisely targeting and removing cancerous lesions.
  • Unlike traditional techniques, it eliminates the need for wires, providing increased scheduling flexibility for surgeons and a better patient experience.
  • During surgery, the surgeon is directed using real-time 3D guidance on the MOLLI® Tablet to the precise location of the lesion.
  • "At MOLLI Surgical, our relentless focus is on the patient, placing their well-being at the core of all our efforts," said Ananth Ravi, President and CEO of MOLLI Surgical.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Lung, TUSC2, Agonal respiration, Metabolism, Gene, Apoptosis, Cell, NSCLC, Nanoparticle, Patient, Neoplasm, Research, Pembrolizumab, Date, NPRL2, Lung cancer, Immunity, ATP, ALK, Glycolysis

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which is being held April 5-10, 2024 in San Diego, California.

Key Points: 
  • Alectinib is an ALK-inhibitor commonly used to treat patients with ALK rearrangements such as EML4-ALK positive NSCLCs.
  • This research suggests that REQORSA may be an effective treatment in patients progressing on alectinib.
  • The study found that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect.
  • Study findings suggest that NPRL2 gene therapy induces anti-tumor activity against KRAS/STK11mt tumors through dendritic cell-mediated antigen presentation and cytotoxic immune cell activation.

GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors

Retrieved on: 
Tuesday, April 9, 2024
RCT, Radiation, Brain, Completion, Progression-free survival, Risk, Patient, Lung, SRT, Neoplasm, Research, Indiana University, Breast, Doctor of Philosophy, MD, Quality of life, Trial of the century, Clinical trial, Melanoma, Recurrence, FDA, Craniotomy, Randomized controlled trial, Medical imaging

TEMPE, Ariz., April 9, 2024 /PRNewswire/ -- GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the lives of patients with brain tumors, today announced it has enrolled the 100th patient in its ROADS clinical study. ROADS, or Radiation One and Done Study, is the randomized control trial (RCT) designed to compare FDA-cleared GammaTile with stereotactic radiotherapy (SRT).

Key Points: 
  • ROADS, or Radiation One and Done Study, is the randomized control trial (RCT) designed to compare FDA-cleared GammaTile with stereotactic radiotherapy (SRT).
  • Patients enrolled in the ROADS clinical trial are randomized into two treatment groups following craniotomy with brain metastasis tumor removal: GammaTile implant at the time of surgery versus post-operative SRT.
  • Enrollment in the Phase 3 trial has now surpassed half of the 180 planned patients.
  • Our dedication to the ROADS trial is fueled by our mission to furnish the highest caliber of clinical evidence through randomized trial research.

Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
BRCA, DNA repair, Mitosis, Apoptosis, Breast, PD, RME, Patient, DHX9, Neoplasm, Data, RNA, DNA, Cancer, Accent, Enzyme, AACR, Therapy, Breast cancer, BRCA2, Pharmaceutical industry

LEXINGTON, Mass., April 8, 2024 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a novel class of small molecule precision cancer therapeutics presents advances in cancer targeting, including data on DHX9 and KIF18A inhibitor activity in multiple tumor types, at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

Key Points: 
  • "Accent has expanded the potential of our two lead programs in preclinical investigations, and we are excited for the promise they hold for addressing cancers with high unmet clinical need," said Robert A. Copeland, Ph.D., President, Founder, and Chief Scientific Officer of Accent Therapeutics.
  • "Our results reveal that DHX9 and KIF18A inhibition are potent therapeutic strategies that stand to benefit large patient populations.
  • These findings validate our systematic approach to tapping the rich therapeutic potential of our target space."
  • These data are highlighted in a presentation entitled "DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2."

Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Immunotherapy, Patient, Neoplasm, RNA, Novel, Cancer, AACR, CLEC2D, Therapy, NK, CD161

WALTHAM, Mass., April 8, 2024 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today presented preclinical data supporting the combination potential of IMT-009 with anti-PD1 immunotherapy at the American Association for Cancer Research Annual Meeting (AACR 2024) in San Diego, California.

Key Points: 
  • This need has fueled our work to develop IMT-009 as a differentiated cancer treatment option for patients," said Annalisa D'Andrea, Chief Scientific Officer at Immunitas.
  • "The preclinical data presented at AACR build upon this innovation, supporting potential for clinical benefit through combination approaches featuring IMT-009 and anti-PD-1 treatments."
  • The data presented at AACR 2024 build upon these preclinical data, reinforcing CD161 as a rational immunotherapy target with the potential to enhance T cell-mediated anti-tumor activity across a range of tumors.
  • Together these data support clinical assessment of IMT-009 treatment in combination with anti-PD-(L)1 approaches in patients refractory to anti-PD-(L)1 treatment alone.

Onkos Surgical Announces First FDA De Novo Approval of an Antibacterial Coating for Tumor and Revision Orthopaedic Implants

Retrieved on: 
Monday, April 8, 2024
Failure, De novo, Health, Prevalence, Infection, Arthroplasty, Patient, Trauma, Mortality, Bacteria, Osteoporosis, Food and Drug Administration, Neoplasm, Amputation, FDA, Onko, Pharmaceutical industry

PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor, trauma, and revision surgery, announced that the U.S. Food & Drug Administration (FDA) granted the company a De Novo approval for its novel antibacterial coated implants. Bacterial contamination of a permanent implant may have devastating effects, particularly in orthopedic oncology and revision arthroplasty applications where the patient population is highly vulnerable.

Key Points: 
  • PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor, trauma, and revision surgery, announced that the U.S. Food & Drug Administration (FDA) granted the company a De Novo approval for its novel antibacterial coated implants.
  • Bacterial contamination of a permanent implant may have devastating effects, particularly in orthopedic oncology and revision arthroplasty applications where the patient population is highly vulnerable.
  • "Implant contamination is a growing concern to the orthopaedic surgical community," said Steven Gitelis, MD, Onkos Surgical Chief Medical Officer, Rush Medical College, Endowed Professor of Orthopaedic Oncology and Director, Musculoskeletal Oncology at Rush Cancer Center.
  • The Onkos technology is a significant innovation and another option to help reduce local bacterial load on the implant."

Sapience Therapeutics Presents Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Research, BCL9, MDSC, Survival, Patient, Wisdom, SVP, Neoplasm, The central science, Cancer, Macrophage, AP-1, IND, AACR, TAM, Phenotype, Therapy, Breast cancer, Poster, Cell, AP-1 transcription factor, TNBC, Metastasis, Vaccine

TARRYTOWN, N.Y., April 8, 2024 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced the presentation of new data on its clinical and pipeline programs during three poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, CA.

Key Points: 
  • We look forward to ST316 and ST101 continuing to advance through clinical development and moving our AP-1 program into IND-enabling studies."
  • Sapience scientists will present non-clinical immune-oncology results from both of its clinical programs, ST316, a first-in-class antagonist of β-catenin, and ST101, a first-in-class antagonist of C/EBPβ.
  • In nonclinical studies, Sapience evaluated the ability of ST316 to enhance anti-tumor immune responses in combination with anti-PD-1 and anti-TIGIT therapies.
  • JunAP demonstrates potent anti-tumor activity in vivo in mouse triple negative breast cancer and melanoma tumor models.

Blue Faery Awards Liver Cancer Research Grant

Retrieved on: 
Monday, April 8, 2024
HCC, Research, Fairy, Internal medicine, Liver cancer, AstraZeneca, Professor, Caregiver, Patient, Education, Hepatocellular carcinoma, Heidelberg University, Culture, Teaching hospital, University of Marburg, Neoplasm, Cancer, LOS, Gastrointestinal disease, Multimedia, BFA

LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), is the third leading cause of cancer deaths worldwide. Blue Faery created the award to recognize medical professionals who do innovative HCC research.

Key Points: 
  • Dr. Peter Galle, Professor and Chairman at University Medical Center Mainz, wins a $25K grant
    LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research.
  • Blue Faery's mission is to prevent, treat, and cure primary liver cancer through research, education, and advocacy.
  • Blue Faery provides free comprehensive patient education with its Patient Resource Guides for Liver Cancer .
  • Blue Faery has three public education and awareness programs: Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Retrieved on: 
Monday, April 8, 2024
ACT, Gene, Biotechnology, Acceleration, LOH, CDX, Risk, Patient, NGS, Biomarker, Research, MSI, DNA, Cancer, Spacecraft, AACR, MRD, Recurrence, FDA, Health, Plasma, Neoplasm, Medicine, Pharmaceutical industry

BURLINGTON, N.C., April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.

Key Points: 
  • The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.
  • "Our portfolio expansion enhances our integrated services to empower our partners with the solutions and support they need to advance their development programs and make a lasting difference in patients' lives."
  • Labcorp recently announced the commercial availability of Labcorp Plasma Detect, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) MRD solution for research and investigational use.
  • Labcorp's deep scientific expertise and comprehensive solutions include specialized pre-clinical discovery, biomarker and companion diagnostics (CDx) development and post-commercialization capabilities.

Element Biosciences Announces Availability of AVITI24, the First Benchtop Sequencer Capable of Direct Cell Profiling

Retrieved on: 
Friday, April 5, 2024
MAPK, Today, Science, SAN, DSM-IV codes, Neoplasm, Research, RNA, DNA, Element, Cancer, Neuroscience, Doctor of Philosophy, Protein, AACR, Drug development, Phosphoprotein, Annual general meeting, Vaccine

SAN DIEGO, April 5, 2024 /PRNewswire/ -- Element Biosciences, Inc., developer of pioneering technologies to empower science, has begun taking orders for AVITI24™ the first instrument to combine state-of-the-art sequencing and cyto-profiling (mapping cell characteristics) into a single integrated biology platform, the company announced at the Annual Meeting of the American Association for Cancer Research.

Key Points: 
  • AVITI24 revolutionizes research by enabling simultaneous examination of DNA, RNA, proteins, phosphoproteins, and cell structure within single cells.
  • Powered by Element's new Teton™ chemistry, AVITI24 expands on AVITI's best-in-class sequencing capabilities to offer new multi-omics functionality, simplifying results in one multi-omic read-out in less than 24 hours.
  • This technology is particularly relevant for cancer researchers, facilitating in-depth exploration of the links between the molecular makeup of cancer cells and how they function within complex tumors.
  • "Today, we are redefining what a sequencer can do by streamlining multiple conventional stages of discovery into a single powerful platform," said Molly He, PhD, CEO and co-founder of Element Biosciences.